CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and often overlooked complication.

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on January 14.Stay Ahead of the ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive internal research license. DUBLIN and CHESHIRE, United Kingdom ...